ATLANTA — February 28, 2011 — A sharp decline in breast cancer incidence rates among non-Hispanic white women in the U.S. after a dramatic drop in the use of postmenopausal hormone therapy did not continue through 2007, according to a new study from the American Cancer Society and the National Cancer Institute. While there are several possible explanations for the recent stabilization, it may indicate that the decrease in breast cancers thought to be related to postmenopausal hormone use has bottomed out. The study appears online in Cancer Epidemiology Biomarkers and Prevention and will appear in a future print issue.
Breast cancer incidence rates among U.S. white women dropped by about 7% between 2002 and 2003 after a dramatic drop in the use of postmenopausal hormone therapy (HT) prompted by the Women’s Health Initiative (WHI) study findings in July 2002 on the adverse health effects of combined HT use, including increased risk of breast cancer. To see if that trend continued, researchers led by Carol DeSantis, MPH reviewed data on female invasive breast cancer incidence obtained from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) 12 registries for the years 2000-2007. They found the sharp decline in breast cancer incidence rates in non-Hispanic white women between 2002 and 2003 did not continue between 2003 and 2007. There was no significant change in the overall incidence rate for breast cancer among non-Hispanic white women during those years. Meanwhile, non-Hispanic Black and Hispanic women did not experience the steep drop in incidence from 2002-2003 and there were no significant changes in incidence rates among those groups from 2003-2007.
The authors say there are several possible explanations for the recent stabilization in breast cancer incidence rates among non-Hispanic white women in the U.S. First, although the report indicates that postmenopausal HT use has continued to decline through 2008, the decrease in HT use after 2003 may not have been large enough to continue delaying diagnoses. Second, the trends may reflect improved sensitivity of mammography without influence of HT, since HT increases breast density and compromises the diagnostic performance of mammograms and breast biopsies. Also, the rates may in part reflect the relatively stable rates of screening mammography in the U.S. since 2000. Increasing screening rates would have likely increased the number of diagnoses.
About the American Cancer Society
The American Cancer Society combines an unyielding passion with nearly a century of experience to save lives and end suffering from cancer. As a global grassroots force of more than three million volunteers, we fight for every birthday threatened by every cancer in every community. We save lives by helping people stay well by preventing cancer or detecting it early; helping people get well by being there for them during and after a cancer diagnosis; by finding cures through investment in groundbreaking discovery; and by fighting back by rallying lawmakers to pass laws to defeat cancer and by rallying communities worldwide to join the fight. As the nation’s largest non-governmental investor in cancer research, contributing about $3.4 billion, we turn what we know about cancer into what we do. As a result, more than 11 million people in America who have had cancer and countless more who have avoided it will be celebrating birthdays this year. To learn more about us or to get help, call us any time, day or night, at 1-800-227-2345 or visit cancer.org.
